Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific ACTN1 ENSG00000072110 Actinin, alpha 1 14 68874143-68979440 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004303, HPA006035 Approved Validated Plasma membrane
Focal adhesion sites Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 744.4 ALKBH6 MGC15677 ENSG00000239382 AlkB homolog 6 19 36009120-36014239 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA073835, HPA074340 Supported Nucleoplasm
Focal adhesion sites Expressed in all Mixed cerebral cortex: 7.5 ARHGAP4 C1, KIAA0131, p115, RhoGAP4, SrGAP4 ENSG00000089820 Rho GTPase activating protein 4 X 153907367-153934999 Predicted intracellular proteins Evidence at protein level HPA001012, HPA001083 Supported Approved Nucleoplasm
Focal adhesion sites Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable) Expressed in all Tissue enhanced spleen: 96.8 lymph node: 88.6 ATP2C2 KIAA0703, SPCA2 ENSG00000064270 ATPase, Ca++ transporting, type 2C, member 2 16 84368527-84464187 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA052262, HPA075812 Approved Approved Plasma membrane
Focal adhesion sites Endometrial cancer:6.20e-6 (favourable) Mixed Tissue enhanced rectum: 39.0 skin: 30.1 C4orf36 MGC26744 ENSG00000163633 Chromosome 4 open reading frame 36 4 86876205-86936202 Predicted intracellular proteins Evidence at protein level HPA057434 Uncertain Approved Focal adhesion sites
Cytosol Renal cancer:7.69e-5 (favourable) Mixed Tissue enhanced testis: 11.0 skin: 5.9 C9orf172 ENSG00000232434 Chromosome 9 open reading frame 172 9 136844415-136848801 Predicted intracellular proteins Evidence at protein level HPA021200 Uncertain Approved Focal adhesion sites
Cytosol Expressed in all Tissue enhanced cerebral cortex: 7.4 spleen: 3.4 CAPN12 ENSG00000182472 Calpain 12 19 38730187-38769904 Enzymes, Predicted intracellular proteins Evidence at protein level HPA043492, HPA053322 Uncertain Approved Nucleoplasm
Focal adhesion sites Renal cancer:5.90e-6 (unfavourable) Mixed Tissue enriched 7 gallbladder: 35.0 cervix, uterine: 4.7 CARD6 CINCIN1 ENSG00000132357 Caspase recruitment domain family, member 6 5 40841184-40860175 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036438 Uncertain Approved Focal adhesion sites
Cytosol Expressed in all Mixed spleen: 17.2 CHRNA5 ENSG00000169684 Cholinergic receptor, nicotinic, alpha 5 (neuronal) 15 78565520-78595269 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054381 Approved Approved Plasma membrane
Focal adhesion sites Lung cancer:3.64e-5 (unfavourable) Mixed Mixed gallbladder: 6.9 CORO2B ClipinC, KIAA0925 ENSG00000103647 Coronin, actin binding protein, 2B 15 68578969-68727806 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA017960 Approved Approved Plasma membrane
Focal adhesion sites Group enriched Tissue enhanced cerebral cortex: 73.5;fallopian tube: 36.2 ovary: 17.8 CUTA ACHAP, C6orf82 ENSG00000112514 CutA divalent cation tolerance homolog (E. coli) 6 33416442-33418317 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016787, HPA064369 Uncertain Approved Plasma membrane
Focal adhesion sites Lung cancer:8.50e-4 (favourable) Expressed in all Expressed in all thyroid gland: 292.6 DCAF6 IQWD1, PC326 ENSG00000143164 DDB1 and CUL4 associated factor 6 1 167935783-168075843 Predicted intracellular proteins Evidence at protein level HPA054305 Supported Nucleus
Focal adhesion sites Expressed in all Expressed in all skeletal muscle: 223.5 DOK6 DOK5L, HsT3226, MGC20785 ENSG00000206052 Docking protein 6 18 69401055-69849087 Predicted intracellular proteins Evidence at protein level HPA041099, HPA063534 Approved Approved Focal adhesion sites
Cytosol Mixed Tissue enhanced cerebral cortex: 21.1 placenta: 8.4 EMC4 FLJ90746, MGC24415, PIG17, TMEM85 ENSG00000128463 ER membrane protein complex subunit 4 15 34224999-34230156 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026868, HPA053440 Approved Approved Cell Junctions
Focal adhesion sites Expressed in all Expressed in all epididymis: 120.7 EXD3 FLJ20433, LOC54932, mut-7 ENSG00000187609 Exonuclease 3'-5' domain containing 3 9 137306896-137423262 Predicted intracellular proteins Evidence at transcript level HPA047395 Approved Approved Actin filaments
Focal adhesion sites Endometrial cancer:4.30e-4 (favourable) Expressed in all Mixed duodenum,small intestine,spleen: 10.2 FBXO28 CENP-30, Fbx28, FLJ10766, KIAA0483 ENSG00000143756 F-box protein 28 1 224114087-224162047 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003289 Approved Nucleoplasm
Focal adhesion sites Expressed in all Expressed in all skin: 25.0 FERMT2 KIND2, mig-2, PLEKHC1, UNC112B ENSG00000073712 Fermitin family member 2 14 52857268-52952435 Predicted intracellular proteins Evidence at protein level HPA040505 Uncertain Supported Nucleoplasm
Focal adhesion sites Expressed in all Mixed smooth muscle: 220.5 FHL2 DRAL, SLIM3 ENSG00000115641 Four and a half LIM domains 2 2 105357712-105438513 Predicted intracellular proteins Evidence at protein level HPA005922, HPA006028, CAB008368 Supported Validated Actin filaments
Focal adhesion sites Renal cancer:6.42e-5 (unfavourable), Head and neck cancer:2.01e-4 (unfavourable) Expressed in all Expressed in all ovary: 657.3 GIT1 ENSG00000108262 G protein-coupled receptor kinase interacting ArfGAP 1 17 29573469-29594054 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004059, HPA004186 Approved Validated Focal adhesion sites
Cytosol Liver cancer:2.54e-6 (unfavourable) Expressed in all Expressed in all testis: 127.5 HAUS4 C14orf94, FLJ20424 ENSG00000092036 HAUS augmin-like complex, subunit 4 14 22946228-22957161 Predicted intracellular proteins Evidence at protein level HPA029803, HPA071195 Approved Supported Plasma membrane
Focal adhesion sites Urothelial cancer:2.24e-4 (unfavourable) Expressed in all Expressed in all ovary: 61.7 HENMT1 C1orf59, FLJ30525, HEN1 ENSG00000162639 HEN1 methyltransferase homolog 1 (Arabidopsis) 1 108648290-108661526 Enzymes, Predicted intracellular proteins Evidence at protein level HPA028464, HPA028497 Uncertain Approved Plasma membrane
Focal adhesion sites Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable) Expressed in all Tissue enriched 8 testis: 127.7 lymph node: 15.0 HRASLS H-REV107, HRASLS1 ENSG00000127252 HRAS-like suppressor 3 193241125-193277738 Predicted membrane proteins Evidence at transcript level HPA051179 Uncertain Approved Focal adhesion sites
Cytosol Testis cancer:4.36e-4 (favourable) Mixed Group enriched 6 skeletal muscle: 27.2;testis: 95.4 thyroid gland: 10.0 ILK ENSG00000166333 Integrin-linked kinase 11 6603708-6610874 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004041, HPA048437 Supported Validated Cell Junctions
Focal adhesion sites Renal cancer:2.44e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 554.5 ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin, alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002499, HPA004856 Supported Approved Focal adhesion sites
Cytosol Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 187.7 LIMD1 ENSG00000144791 LIM domains containing 1 3 45555394-45686338 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA064220 Supported Nucleus
Focal adhesion sites Renal cancer:6.73e-5 (favourable) Expressed in all Expressed in all lung: 26.8 LIMS1 PINCH, PINCH1 ENSG00000169756 LIM and senescent cell antigen-like domains 1 2 108534355-108687246 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058455, HPA061230 Approved Supported Focal adhesion sites
Cytosol Renal cancer:7.88e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 59.7 LIMS3 ENSG00000256977 LIM and senescent cell antigen-like domains 3 2 109898428-109924868 Predicted intracellular proteins Evidence at transcript level HPA058455 Uncertain Approved Focal adhesion sites
Cytosol Not detected Tissue enhanced fallopian tube: 9.8 endometrium: 8.8 LMLN Gp63, Msp ENSG00000185621 Leishmanolysin-like (metallopeptidase M8 family) 3 197960200-198043720 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016481, HPA028844 Uncertain Supported Focal adhesion sites
Cytosol Endometrial cancer:6.77e-4 (favourable) Expressed in all Tissue enhanced testis: 18.7 epididymis: 12.7 LPP ENSG00000145012 LIM domain containing preferred translocation partner in lipoma 3 188153284-188890671 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA011133, HPA017342 Supported Validated Focal adhesion sites
Cytosol Expressed in all Expressed in all smooth muscle: 116.9 MISP C19orf21, Caprice, DKFZp686H18209 ENSG00000099812 Mitotic spindle positioning 19 751126-764318 Predicted intracellular proteins Evidence at protein level HPA049511, HPA062232 Supported Validated Plasma membrane
Focal adhesion sites Tissue enhanced Group enriched 6 colon: 96.4;duodenum: 178.1;rectum: 53.5;small intestine: 221.5 stomach: 22.1 MYO5A GS1, MYH12, MYO5, MYR12 ENSG00000197535 Myosin VA 15 52307283-52529050 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001356 Approved Approved Focal adhesion sites
Microtubule organizing center Urothelial cancer:4.22e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 94.6 NOB1 ART-4, MST158, NOB1P, PSMD8BP1 ENSG00000141101 NIN1/RPN12 binding protein 1 homolog 16 69741867-69754940 Predicted intracellular proteins Evidence at protein level HPA041522, HPA049430, HPA067411 Approved Approved Focal adhesion sites
Cytosol Head and neck cancer:4.21e-5 (unfavourable), Liver cancer:8.16e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 69.0 PDLIM2 ENSG00000120913 PDZ and LIM domain 2 (mystique) 8 22578279-22598025 Predicted intracellular proteins Evidence at protein level HPA003880 Approved Approved Actin filaments
Focal adhesion sites Renal cancer:1.37e-7 (unfavourable), Glioma:7.23e-4 (unfavourable) Expressed in all Expressed in all spleen: 273.0 PDLIM7 ENIGMA ENSG00000196923 PDZ and LIM domain 7 (enigma) 5 177483394-177497606 Predicted intracellular proteins Evidence at protein level HPA018794, HPA048815 Approved Validated Actin filaments
Focal adhesion sites Renal cancer:6.19e-10 (unfavourable), Lung cancer:4.07e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 285.6 PNMA1 MA1 ENSG00000176903 Paraneoplastic Ma antigen 1 14 73711783-73714372 Predicted intracellular proteins Evidence at protein level HPA003817, HPA015007 Supported Supported Focal adhesion sites
Cytosol Liver cancer:3.00e-5 (unfavourable), Urothelial cancer:4.51e-5 (unfavourable), Head and neck cancer:7.49e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 194.0 PPFIA1 LIP.1, LIPRIN ENSG00000131626 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 11 70270700-70384403 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008272, CAB017032, HPA042271 Uncertain Validated Focal adhesion sites
Cytosol Renal cancer:3.76e-4 (favourable), Head and neck cancer:5.58e-4 (unfavourable), Pancreatic cancer:8.26e-4 (unfavourable) Expressed in all Expressed in all testis: 56.9 PWWP2A KIAA1935 ENSG00000170234 PWWP domain containing 2A 5 160061801-160119423 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA046733, HPA058233 Uncertain Supported Nucleoplasm
Focal adhesion sites Urothelial cancer:3.51e-4 (favourable), Renal cancer:3.70e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 15.4 PXN ENSG00000089159 Paxillin 12 120210439-120265771 Predicted intracellular proteins Evidence at protein level CAB003841, HPA051309 Supported Validated Focal adhesion sites
Cytosol Head and neck cancer:3.72e-5 (unfavourable), Glioma:6.11e-5 (unfavourable), Liver cancer:7.12e-5 (unfavourable), Lung cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all placenta: 112.3 RAET1E bA350J20.7, LETAL, ULBP4 ENSG00000164520 Retinoic acid early transcript 1E 6 149883375-149898102 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054022 Approved Focal adhesion sites
Cytosol Tissue enhanced Tissue enhanced esophagus: 71.1;skin: 29.0 tonsil: 10.8 RASAL2 nGAP ENSG00000075391 RAS protein activator like 2 1 178094141-178484147 Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA018805, HPA020453 Approved Approved Plasma membrane
Focal adhesion sites Urothelial cancer:2.05e-4 (unfavourable) Expressed in all Mixed esophagus: 19.5 RELN PRO1598, RL ENSG00000189056 Reelin 7 103471784-103989516 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046512 Approved Plasma membrane
Focal adhesion sites Tissue enhanced Tissue enhanced liver: 17.8 cerebral cortex: 7.3 RP11-298I3.5 ENSG00000259132 14 22946270-22982258 Predicted intracellular proteins Evidence at protein level HPA029803 Approved Approved Plasma membrane
Focal adhesion sites Not detected Mixed lymph node: 9.2 SENP1 ENSG00000079387 SUMO1/sentrin specific peptidase 1 12 48042898-48106308 Enzymes, Predicted intracellular proteins Evidence at protein level HPA011765, HPA046491 Uncertain Validated Nucleus
Focal adhesion sites Liver cancer:7.72e-5 (unfavourable), Renal cancer:8.37e-4 (unfavourable) Expressed in all Tissue enriched 8 testis: 109.5 lymph node: 13.4 SIKE1 FLJ21168, SIKE ENSG00000052723 Suppressor of IKBKE 1 1 114769479-114780685 Predicted intracellular proteins Evidence at protein level HPA024177, HPA025726 Supported Approved Vesicles
Focal adhesion sites Expressed in all Expressed in all thyroid gland: 19.3 SLC16A8 MCT3, REMP ENSG00000100156 Solute carrier family 16 (monocarboxylate transporter), member 8 22 38078134-38084093 Plasma proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA075017 Approved Intermediate filaments
Focal adhesion sites Mixed Mixed prostate: 5.7 SLC4A7 NBC3, SBC2, SLC4A6 ENSG00000033867 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 3 27372721-27484420 Predicted membrane proteins, Transporters Evidence at protein level CAB022494, HPA035857 Supported Supported Plasma membrane
Focal adhesion sites Renal cancer:7.91e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 59.2 breast: 23.6 SNX32 FLJ30934, SNX6B ENSG00000172803 Sorting nexin 32 11 65833641-65856896 Predicted intracellular proteins Evidence at protein level HPA041775 Uncertain Uncertain Cell Junctions
Focal adhesion sites Mixed Tissue enhanced cerebral cortex: 7.8 testis: 1.7 SORBS3 SCAM-1, SH3D4, vinexin ENSG00000120896 Sorbin and SH3 domain containing 3 8 22544986-22575788 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015849, HPA048034 Approved Approved Nucleoplasm
Focal adhesion sites Urothelial cancer:1.53e-5 (unfavourable), Pancreatic cancer:4.88e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 95.0 SRP68 ENSG00000167881 Signal recognition particle 68kDa 17 76038775-76072653 Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA023303, HPA055617 Approved Validated Focal adhesion sites
Cytosol Liver cancer:4.28e-5 (unfavourable), Head and neck cancer:2.18e-4 (unfavourable), Thyroid cancer:2.65e-4 (favourable) Expressed in all Expressed in all thyroid gland: 71.7 TGFB1I1 ARA55, Hic-5, TSC-5 ENSG00000140682 Transforming growth factor beta 1 induced transcript 1 16 31471585-31477960 Predicted intracellular proteins Evidence at protein level CAB020844 Approved Supported Focal adhesion sites
Cytosol Renal cancer:6.06e-8 (unfavourable), Urothelial cancer:7.73e-5 (unfavourable) Expressed in all Tissue enhanced endometrium: 139.7;smooth muscle: 151.9 seminal vesicle: 109.6 TLE2 ESG, ESG2, FLJ41188, GRG2 ENSG00000065717 Transducin-like enhancer of split 2 19 2997638-3047635 Predicted intracellular proteins Evidence at protein level HPA049103 Approved Supported Nuclear bodies
Focal adhesion sites Pancreatic cancer:2.39e-6 (favourable), Renal cancer:9.49e-6 (favourable), Endometrial cancer:2.51e-4 (favourable), Urothelial cancer:8.88e-4 (favourable) Expressed in all Mixed seminal vesicle: 39.1 TLN2 ILWEQ, KIAA0320 ENSG00000171914 Talin 2 15 62390526-62844631 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB017194 Approved Supported Focal adhesion sites
Cytosol Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 41.0;kidney: 40.3 thyroid gland: 21.5 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 TMEM139 FLJ90586 ENSG00000178826 Transmembrane protein 139 7 143279957-143288048 Predicted membrane proteins, Transporters Evidence at protein level HPA036982, HPA036983 Approved Approved Plasma membrane
Focal adhesion sites Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable) Mixed Tissue enhanced duodenum: 34.9;kidney: 34.4 small intestine: 21.2 TMEM53 FLJ22353, NET4 ENSG00000126106 Transmembrane protein 53 1 44635238-44674555 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021134 Approved Approved Golgi apparatus
Focal adhesion sites Renal cancer:1.02e-5 (favourable), Ovarian cancer:6.96e-4 (favourable) Expressed in all Mixed testis: 23.3 TRIM62 DEAR1, FLJ10759 ENSG00000116525 Tripartite motif containing 62 1 33145402-33182059 Predicted intracellular proteins Evidence at protein level HPA050061 Approved Vesicles
Focal adhesion sites Renal cancer:7.08e-5 (unfavourable) Expressed in all Mixed skin: 11.6 TRPC7 ENSG00000069018 Transient receptor potential cation channel, subfamily C, member 7 5 136213320-136365537 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB022592, HPA031126 Uncertain Uncertain Actin filaments
Focal adhesion sites Not detected Not detected testis: 0.7 ZBTB8A BOZF1, FLJ90065, ZBTB8, ZNF916A ENSG00000160062 Zinc finger and BTB domain containing 8A 1 32539427-32605939 Predicted intracellular proteins Evidence at protein level HPA031768, HPA031769, HPA031770 Approved Approved Nuclear speckles
Focal adhesion sites Expressed in all Mixed endometrium: 10.2